Reduction in central retinal thickness at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in reduction in central retinal thickness at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
No problems in quality of life domains at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in no problems in quality of life domains at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
RR 0.51 [0.05, 5.62]
1670 participants
Moderate
BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in gain of 15 or more letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in loss of fewer than 15 letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
Symptomatic improvement · adults with dry eye syndrome
1 finding from 1 review
Tear film stability · adults with dry eye syndrome
1 finding from 1 review
Artificial tear use · adults with dry eye syndrome
1 finding from 1 review
Adverse events · adults with dry eye syndrome
1 finding from 1 review
Symptomatic improvement · adults with dry eye syndrome
It is very uncertain whether summary of findings: punctal plugs changes symptomatic improvement compared with oral pilocarpine (very low certainty).
1 finding from 1 review
Ocular surface staining · adults with dry eye syndrome
1 finding from 1 review
Aqueous tear production · adults with dry eye syndrome
1 finding from 1 review
Tear film stability · adults with dry eye syndrome
The review found no eligible studies for this question.
1 finding from 1 review
Artificial tear use · adults with dry eye syndrome
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · adults with dry eye syndrome
1 finding from 1 review
Symptomatic improvement · adults with dry eye syndrome
It is very uncertain whether summary of findings: punctal plugs changes symptomatic improvement compared with artificial tears (very low certainty).
1 finding from 1 review
Ocular surface staining · adults with dry eye syndrome
1 finding from 1 review
Ocular surface staining · adults with dry eye syndrome
1 finding from 1 review
Aqueous tear production · adults with dry eye syndrome
1 finding from 1 review